Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter August 5, 2019

Interferences in free thyroxine concentration using the Roche analytical platform: improvement of the third generation?

  • Isabelle Ruth , Elise Mathieu , Agnès Burniat , David Fage , Frédéric Cotton and Fleur Wolff EMAIL logo
  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Piketty ML, Polak M, Flechtner I, Gonzales-Briceño L, Souberbielle JC. False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays: the problem of biotin intake and related interferences. Clin Chem Lab Med 2017;55:780–8.10.1515/cclm-2016-0606Search in Google Scholar PubMed

2. Favresse J, Burlacu M-C, Maiter D, Gruson D. Interferences with thyroid function immunoassays: clinical implications and detection algorithm. Endocr Rev 2018;39:830–50.10.1210/er.2018-00119Search in Google Scholar PubMed

3. Rulander NJ, Cardamone D, Senior M, Snyder PJ, Master SR. Interference from anti-streptavidin antibody. Arch Pathol Lab Med 2013;137:1141–6.10.5858/arpa.2012-0270-CRSearch in Google Scholar PubMed

4. Luong JH, Male KB, Glennon JD. Biotin interference in immunoassays based on biotin-strept(avidin) chemistry: an emerging threat. Biotechnol Adv 2019;37:634–41.10.1016/j.biotechadv.2019.03.007Search in Google Scholar PubMed

5. Roche Diagnostics. Method Sheet, Elecsys FT4III. 2019-01, V1.0, English.Search in Google Scholar

6. Roche Diagnostics. Reference intervals for children and adults. Elecsys and Cobas e analyzers, Elecsys Thyroid Tests 2007;72:641–8.Search in Google Scholar

7. Piketty ML, Prie D, Sedel F, Bernard D, Hercend C, Chanson P, et al. High-dose biotin therapy leading to false biochemical endocrine profiles: validation of a simple method to overcome biotin interference. Clin Chem Lab Med 2017;55:817–25.10.1515/cclm-2016-1183Search in Google Scholar PubMed

8. Peltier L, Massart C, Moineau MP, Delhostal A, Roudaut N. Anti-streptavidin interferences in Roche thyroid immunoassays: a case report. Clin Chem Lab Med 2016;54:e11–4.10.1515/cclm-2015-0350Search in Google Scholar PubMed

9. Sebastian Kummer MD, Derik Hermsen MD, Felix Distelmaier M. Biotin treatment mimicking Graves’ disease. N Engl J Med 2016;375:704–6.10.1056/NEJMc1602096Search in Google Scholar PubMed

10. Elston MS, Sehgal S, Du Toit S, Yarndley T, Conaglen JV. Factitious Graves’ disease due to biotin immunoassay interference – a case and review of the literature. J Clin Endocrinol Metab 2016;101:3251–5.10.1210/jc.2016-1971Search in Google Scholar PubMed

11. Bayart JL, Favresse J, Melnik E, Lardinois B, Fillée C, Maiter D, et al. Erroneous thyroid and steroid hormones profiles due to anti-streptavidin antibodies. Clin Chem Lab Med 2019;57:e255–8.10.1515/cclm-2018-1355Search in Google Scholar PubMed

12. Gifford JL, de Koning L, Sadrzadeh SM. Strategies for mitigating risk posed by biotin interference on clinical immunoassays. Clin Biochem 2019;65:61–3.10.1016/j.clinbiochem.2018.12.007Search in Google Scholar PubMed

13. Sedel F, Papeix C, Bellanger A, Touitou V, Lebrun-Frenay C, Galanaud D, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord 2015;4:159–69.10.1016/j.msard.2015.01.005Search in Google Scholar PubMed

14. Li J, Wagar EA, Meng QH. Comprehensive assessment of biotin interference in immunoassays. Clin Chim Acta 2018;487:293–8.10.1016/j.cca.2018.10.013Search in Google Scholar PubMed

15. Peyro Saint Paul L, Debruyne D, Bernard D, Mock DM, Defer GL. Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis. Expert Opin Drug Metab Toxicol 2015;12:327–44.10.1517/17425255.2016.1136288Search in Google Scholar PubMed

16. Katzman BM, Lueke AJ, Donato LJ, Jaffe AS, Baumann NA. Prevalence of biotin supplement usage in outpatients and plasma biotin concentrations in patients presenting to the emergency department. Clin Biochem 2018;60:11–6.10.1016/j.clinbiochem.2018.07.004Search in Google Scholar PubMed

Received: 2019-05-27
Accepted: 2019-07-16
Published Online: 2019-08-05
Published in Print: 2020-01-28

© 2019 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 28.3.2024 from https://www.degruyter.com/document/doi/10.1515/cclm-2019-0525/html
Scroll to top button